Research presented at the American Academy of Ophthalmology meeting suggests that decreasing vitamin A dimerization with oral gildeuretinol may be an effective treatment for geographic atrophy related to age-related macular degeneration. The phase 3 SAGA study showed a reduction in lesion growth rate and a significant improvement in low-luminance visual acuity in patients treated with gildeuretinol compared to placebo. The study also reported a positive safety profile for the treatment, with most adverse events being mild to moderate. This research suggests that gildeuretinol may be a promising avenue for treating geographic atrophy.
Source link
Oral treatment aims to reduce GA progression by slowing vitamin A dimerization
